- Oops!Something went wrong.Please try again later.
If government regulators around the world thought Big Tech was too big last year, 2021 has not changed their mind.
Investors are nervous about a Food and Drug Administration advisory panel meeting and optimistic about a World Health Organization decision.
How are we going to find a way forward in today’s market environment? The general trend is upwards – the S&P 500 has gained 20% so far this year, and the NASDAQ is close behind at 19% – but market strategists at Goldman Sachs are predicting a pull back before the end of the year, and have scaled back their growth forecast for the S&P to from 6.2% to 5.7%. August’s weak jobs report and rising inflation prompted their shift. Looking at the headwinds, Goldman’s Ronnie Walker says, “The Delta varian
The agency is allowing Lilly's product to be used as a prophylaxis in people who have been exposed to the virus.
As retailers gear up for the holiday season, a record number of container ships trying to bring imported goods into the US are stuck off the coast of California, another casualty of ongoing disruptions to the global supply chain. Sixty-five vessels were waiting to dock at the ports of Los Angeles and Long Beach in the San Pedro Bay Sept. 16, according to the Marine Exchange of Southern California, a record high. Captain Kip Louttit of the Marine Exchange told Quartz that an unprecedented 23 of these ships are in a drift area—meaning there is no room for them to anchor in the water.
Five months ago, stock for Advanced Micro Devices (NASDAQ: AMD) and Micron Technology (NASDAQ: MU) were following different trajectories when it came to their prices. Micron started the year on a positive note thanks to the terrific demand for memory chips, while AMD was struggling in the wake of the sell-off in tech stocks and market share gains clocked by Intel. Micron, on the other hand, has lost investor confidence due to concerns about the health of the memory market.
In this article, we discuss the 10 stocks that analysts are downgrading. If you want to skip our detailed analysis of these stocks, go directly to Analysts Are Downgrading These 5 Stocks. The post-pandemic economic recovery has hit roadblocks in the past few days as new unemployment data pours in, major Wall Street indexes register […]
When you buy a stock, the worst thing that can happen is that you lose 100% of your investment. Of course, that's not a great outcome, but the downside is smaller than the upside. In other words, when you buy a stock, the upside doesn't stop at 100%.
Gold and silver stocks got clobbered on Thursday as prices of precious metals tanked. It looks like just one of those bad days for gold and silver, but here's what you should really make of this drop. Because precious metals, particularly gold, are considered a safe haven asset against economic uncertainties, their prices are particularly vulnerable to economic data.
Considering that most bear market bounce-back rallies feature wild swings in both directions, this has truly been something special for patient investors. Although the stock market offers no guarantees, history has shown time and again that any double-digit percentage pullback in payment-processing company Visa (NYSE: V) is an opportunity for investors to pounce. One of the biggest reasons Visa is such a success story is the company's cyclical ties.
Thermo Fisher Scientific crushed guidance expectations for 2022 and beyond on Friday, and TMO stock surged to a fresh high.
It's hard to believe these two brand names and market leaders can be bought for less than $20 per share.
Teva Pharmaceutical Industries Limited (NYSE:TEVA) seems to be undervalued on a fundamental basis. However, sometimes stocks are trading below intrinsic value because there are factors external to the current money making capacity of the company. We will examine what can be the cause and the extent of the risk for investing in Teva. We will start our analysis with the balance sheet and long term debt.
Every investor wants a sure return – that’s the way to make money in the markets, after all. With the main indexes all showing strong gains for the year (19% on the S&P 500, and 18% on the NASDAQ), those returns are clearly on the table. But there are some shorter-term downward moves, and plenty of market experts are counseling both optimism and caution. RBC chief U.S. equity strategist Lori Calvasina notes that the upward trend has been both substantial and sustained, and she is revising her mi
If you believe in the country's top multiplex operator, you might want to check out its landlord.
Anjalee Khemlani joins Julie Hyman to take an in-depth analyst on the FDA meeting to determine the efficacy of promoting COVID-19 booster shots at this moment in time and what the impact of this decision could mean for the nation going forward.
Lucid Motors (LCID) shares rose 7% after a bullish Wall Street analyst note along with confirmation from the Environmental Protection Agency that the EV maker's premium tier car has a higher mile range than Tesla's model S (TSLA).
ROSE LifeScience Inc. ("ROSE"), a local Quebec cannabis player, announced a partnership with Tilray Canada Ltd., a Canadian subsidiary of Tilray Inc. (TSX: TLRY), a leading global cannabis-lifestyle and consumer packaged goods company (collectively referred to as "Tilray").
AT&T (NYSE: T) has streamlined its business through two bold moves this year. It spun off DirecTV, AT&T TV, and U-verse into a new stand-alone company in August. AT&T retained a 70% stake in the "new" DirecTV, while the private investment firm TPG bought the remaining 30%.
Agenus Inc (NASDAQ: AGEN) presented final results from the Bal/Zal combination study at the European Society for Medical Oncology (ESMO21) Virtual Conference 2021. Related: Agenus Gains As Balstilimab US Application Accepted For Review In Cervical Cancer. The Phase 2 trial evaluated the combination of Balstilimab and zalifrelimab in patients with recurrent/metastatic (R/M) cervical cancer (CC). In the 125 evaluable patients, the overall objective response rate (ORR) was 26%, with 9% of patients
When Ford Motor Co built its first factory in India in the mid-1990s, U.S. carmakers believed they were buying into a boom - the next China. Last week, Ford took a $2 billion hit https://reut.rs/3nFLvnF to stop making cars in India, following compatriots General Motors Co and Harley-Davidson Inc in closing factories in the country. Among foreigners that remain, Japan's Nissan Motor Co Ltd and even Germany's Volkswagen AG - the world's biggest automaker by sales - each hold less than 1% of a car market once forecast to be the third-largest by 2020, after China and the United States, with annual sales of 5 million.